Clinical Data: Bridging Allogeneic CAR-Gamma Delta T Cell to The Clinic
Time: 2:15 pm
day: Conference Day Two - Track A - PM
Details:
- Tailoring manufacturing platform to expand high-quality engineered gamma delta T products
- Demonstrating preclinical activity of CAR-gamma delta T cells for solid tumors and bautoimmune diseases
- Sharing the clinical data of B7H3 CAR-gamma delta T cell therapy for r/r GBM treatment
